Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Revenue (2016 - 2025)

Historic Revenue for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $134.2 million.

  • Adma Biologics' Revenue rose 1200.36% to $134.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $488.6 million, marking a year-over-year increase of 2762.47%. This contributed to the annual value of $426.5 million for FY2024, which is 6515.46% up from last year.
  • As of Q3 2025, Adma Biologics' Revenue stood at $134.2 million, which was up 1200.36% from $122.0 million recorded in Q2 2025.
  • Adma Biologics' 5-year Revenue high stood at $134.2 million for Q3 2025, and its period low was $16.0 million during Q1 2021.
  • Over the past 5 years, Adma Biologics' median Revenue value was $73.9 million (recorded in 2023), while the average stood at $73.8 million.
  • Per our database at Business Quant, Adma Biologics' Revenue soared by 32062.55% in 2022 and then crashed by 1983.6% in 2023.
  • Quarter analysis of 5 years shows Adma Biologics' Revenue stood at $55.0 million in 2021, then fell by 9.12% to $50.0 million in 2022, then skyrocketed by 47.86% to $73.9 million in 2023, then soared by 59.06% to $117.5 million in 2024, then grew by 14.19% to $134.2 million in 2025.
  • Its Revenue stands at $134.2 million for Q3 2025, versus $122.0 million for Q2 2025 and $114.8 million for Q1 2025.